Immunic (NASDAQ:IMUX) Stock Rating Upgraded by EF Hutton Acquisition Co. I

Immunic (NASDAQ:IMUX) was upgraded by investment analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a note issued to investors on Monday, Zacks.com reports.

A number of other equities research analysts also recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and issued a $28.00 target price on shares of Immunic in a report on Tuesday, July 16th. StockNews.com upgraded shares of Immunic from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. B. Riley assumed coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price on the stock. Leerink Partners restated an “outperform” rating and issued a $5.00 price target on shares of Immunic in a report on Monday, September 9th. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $11.20.

Immunic Stock Up 0.6 %

Shares of NASDAQ IMUX opened at $1.61 on Monday. The company has a market capitalization of $145.03 million, a PE ratio of -0.88 and a beta of 1.82. Immunic has a twelve month low of $0.95 and a twelve month high of $1.92. The firm has a fifty day simple moving average of $1.42 and a 200 day simple moving average of $1.32.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. During the same period last year, the company earned ($0.54) EPS. As a group, equities analysts expect that Immunic will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IMUX. Vanguard Group Inc. increased its position in shares of Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares in the last quarter. Janus Henderson Group PLC bought a new position in Immunic in the 1st quarter valued at about $9,266,000. Sierra Summit Advisors LLC acquired a new position in Immunic during the 4th quarter valued at about $487,000. Ikarian Capital LLC increased its holdings in Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after purchasing an additional 1,162,378 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Immunic in the first quarter worth approximately $25,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.